Brief: Veracyte Announces That New NCCN Guidelines Uniquely Recommend Use Of Decipher Prostate Genomic Test Score To Guide Specific Treatment For Men Following Radical Prostatectomy
14/09/2021 21:10
Sept 14 (Reuters) - Veracyte Inc VCYT.O :
* VERACYTE ANNOUNCES THAT NEW NCCN GUIDELINES UNIQUELY
RECOMMEND
USE OF DECIPHER PROSTATE GENOMIC TEST SCORE TO GUIDE SPECIFIC
TREATMENT FOR MEN FOLLOWING RADICAL PROSTATECTOMY
Source text for Eikon: ID:nBw5HVhqra
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina